vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and INTERGROUP CORP (INTG). Click either name above to swap in a different company.
INTERGROUP CORP is the larger business by last-quarter revenue ($17.3M vs $10.7M, roughly 1.6× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 8.8%, a 14.7% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 19.8%). Over the past eight quarters, INTERGROUP CORP's revenue compounded faster (7.8% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Intergroup Corp is a diversified holding firm operating two core segments: real estate and hotel operations. It owns, manages and leases commercial and residential properties across the U.S., and runs limited-service hotels for leisure and business travelers.
ABUS vs INTG — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $17.3M |
| Net Profit | $2.5M | $1.5M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | 11.6% |
| Net Margin | 23.5% | 8.8% |
| Revenue YoY | 522.2% | 19.8% |
| Net Profit YoY | 112.7% | 155.6% |
| EPS (diluted) | $0.01 | $0.71 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $17.3M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | $10.7M | $16.2M | ||
| Q1 25 | — | $16.8M | ||
| Q4 24 | — | $14.4M | ||
| Q3 24 | — | $16.9M | ||
| Q2 24 | — | $13.4M | ||
| Q1 24 | — | $14.9M |
| Q4 25 | — | $1.5M | ||
| Q3 25 | — | $-535.0K | ||
| Q2 25 | $2.5M | $-2.2M | ||
| Q1 25 | — | $-578.0K | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | — | $-398.0K | ||
| Q2 24 | — | $-4.9M | ||
| Q1 24 | — | $-3.2M |
| Q4 25 | — | 11.6% | ||
| Q3 25 | — | 15.3% | ||
| Q2 25 | 13.9% | 8.1% | ||
| Q1 25 | — | 14.0% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | 4.8% |
| Q4 25 | — | 8.8% | ||
| Q3 25 | — | -3.0% | ||
| Q2 25 | 23.5% | -13.9% | ||
| Q1 25 | — | -3.4% | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | -2.4% | ||
| Q2 24 | — | -36.7% | ||
| Q1 24 | — | -21.3% |
| Q4 25 | — | $0.71 | ||
| Q3 25 | — | $-0.25 | ||
| Q2 25 | $0.01 | — | ||
| Q1 25 | — | $-0.27 | ||
| Q4 24 | — | $-1.26 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-1.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $7.5M |
| Total DebtLower is stronger | $0 | $233.2M |
| Stockholders' EquityBook value | $83.0M | $-85.2M |
| Total Assets | $103.3M | $101.1M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.5M | ||
| Q3 25 | — | $6.0M | ||
| Q2 25 | $37.4M | $6.1M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | $15.4M | ||
| Q3 24 | — | $12.2M | ||
| Q2 24 | — | $11.6M | ||
| Q1 24 | — | $19.5M |
| Q4 25 | — | $233.2M | ||
| Q3 25 | — | $237.8M | ||
| Q2 25 | $0 | $240.5M | ||
| Q1 25 | — | $241.5M | ||
| Q4 24 | — | $227.2M | ||
| Q3 24 | — | $218.1M | ||
| Q2 24 | — | $225.7M | ||
| Q1 24 | — | $225.0M |
| Q4 25 | — | $-85.2M | ||
| Q3 25 | — | $-86.7M | ||
| Q2 25 | $83.0M | $-86.1M | ||
| Q1 25 | — | $-84.5M | ||
| Q4 24 | — | $-83.9M | ||
| Q3 24 | — | $-80.9M | ||
| Q2 24 | — | $-80.3M | ||
| Q1 24 | — | $-76.4M |
| Q4 25 | — | $101.1M | ||
| Q3 25 | — | $102.5M | ||
| Q2 25 | $103.3M | $104.1M | ||
| Q1 25 | — | $103.2M | ||
| Q4 24 | — | $110.6M | ||
| Q3 24 | — | $109.3M | ||
| Q2 24 | — | $107.8M | ||
| Q1 24 | — | $119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-23.0K |
| Free Cash FlowOCF − Capex | — | $-481.0K |
| FCF MarginFCF / Revenue | — | -2.8% |
| Capex IntensityCapex / Revenue | 0.0% | 2.6% |
| Cash ConversionOCF / Net Profit | -6.24× | -0.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | $739.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-23.0K | ||
| Q3 25 | — | $-296.0K | ||
| Q2 25 | $-15.7M | $5.9M | ||
| Q1 25 | — | $-854.0K | ||
| Q4 24 | — | $-781.0K | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $6.8M | ||
| Q1 24 | — | $1.9M |
| Q4 25 | — | $-481.0K | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-1.2M | ||
| Q4 24 | — | $-1.1M | ||
| Q3 24 | — | $3.1M | ||
| Q2 24 | — | $2.7M | ||
| Q1 24 | — | $1.1M |
| Q4 25 | — | -2.8% | ||
| Q3 25 | — | -7.1% | ||
| Q2 25 | — | 22.5% | ||
| Q1 25 | — | -6.8% | ||
| Q4 24 | — | -7.8% | ||
| Q3 24 | — | 18.3% | ||
| Q2 24 | — | 20.4% | ||
| Q1 24 | — | 7.6% |
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | 0.0% | 13.9% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.6% | ||
| Q2 24 | — | 30.4% | ||
| Q1 24 | — | 4.9% |
| Q4 25 | — | -0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
INTG
| Hotel Operations | $12.7M | 73% |
| Real Estate Operation | $4.6M | 27% |
